tigelydin

Tigelydin (HSK21297) is a novel, potent, and selective **mu-opioid receptor (MOR) agonist** developed by **Haisco Pharmaceutical Group**. It is a small molecule analgesic administered intravenously, designed for use in general anesthesia and the management of acute pain, such as postoperative pain. Tigelydin is engineered to provide rapid-onset and potent analgesia with a pharmacokinetic profile that allows for quick recovery, making it suitable for day-case surgeries and procedural sedation. In clinical studies, it is often evaluated as an adjunct to sedatives like remimazolam to provide balanced anesthesia while maintaining hemodynamic stability and minimizing respiratory depression compared to traditional opioids like alfentanil. The drug is currently in Phase 2/3 clinical development for various anesthesia and pain indications, including support for gynecologic procedures like hysteroscopy.

Other names

tigelydintigelydinetigelydin fumarate替格列定